(Formerly LKS98-04)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

" ·			
M. M	nl	100	nt·
KK KK	ועי	ıva	IJι.

Gregory J. LaRosa

Application No.:

09/121,781

Group:

1648

Filed:

July 23, 1998

Examiner: A. Salimi

For:

Anti-CCR2 Antibodies and Methods of Use Therefor

I hereby certify that this corresponding states Postal Service with sufficient	CATE OF MAILING ondence is being deposited with the United int postage as First Class Mail in an envelopement for Patents, Washington, D.C. 20231
	<u>Depelteau</u>
Typed or printed nar	me of person signing certificate

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted:

[]	under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)		
[]	under 37 CFR 1.97(b), or		
	(Within any one of the following time periods: three months of filing national application	on (other than a CPA) or date o	f entry of the
	national stage in an international application; or before the mailing date of a first office a	action on the merits in a non-pr	ovisional
	application, including a CPA, or a Request for Continued Examination).		
[X]	under 37 CFR 1.97(c) together with either:		8
	[] a Statement under 37 CFR 1.97(e), as checked below	v, or	781 180.00 UP
	[X] a \$180.00 fee under 37 CFR 1.17(p), or		09121781 180
	(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, wh	ichever occurs first)	00000045 (
[]	under 37 CFR 1.97(d) together with:	•	
	[] a Statement under 37 CFR 1.97(e), as checked below	v, and	UKOROMA
	[] a \$180.00 fee under 37 CFR 1.17(p), or		/2000 :126

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

12/28/2000 WKOROMA 00000045 09121781

[]	under	37 CFR 1.97(i):		
	Appli	cant requests that the IDS and cited reference(s) be placed in the application		
filewra	pper.			
	(Filed aft	er payment of issue fee)		
Statem	ent Un	der 37 CFR 1.97(e)		
[]	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or			
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.			
Statem	ent Un	der 37 CFR 1.704(d) (Patent Term Adjustment)		
[]	Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.			
[X]	Enclos	Enclosed herewith is form PTO-1449:		
	[X]	Copies of the cited references are enclosed.		
	[]	Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]		
	[]	The listed references were cited in the enclosed International Search Report in a counterpart foreign application.		
Concis	e Expla	anation Requirement (non-English references):		
[X]	The "c	oncise explanation" requirement for reference AQ under 37 CFR 1.98(a)(3) is ed by:		
	[]	the explanation provided on the attached sheet.		
	[]	the explanation provided in the Specification.		
	[]	submission of the enclosed International Search Report.		
	[X]	the English language abstract on the cover page of Reference AQ.		
[]	Applicant requests that the following pending applications be considered:			
Examiner's Initials				
		U.S. Patent Application No. [], by [inventor(s)], filed [] Docket No.: []		

	U.S. Patent Application No. [], by [inventor(s)], filed [] Docket No.: []		
	U.S. Patent Application No. [], by [inventor(s)], filed [] Docket No.: []		
	Examiner Date		
[]	A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the application, including the current claims.]		
The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.			
It is re	quested that the information disclosed herein be made of record in this application.		
Method of payment:			
[X]	A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.		
[]	Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.		
[X]	Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.		
	Respectfully submitted,		

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

Lisa M. Treannie Registration No.: 41,368 Telephone: (781) 861-6240 Facsimile: (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated:

12/19/00